StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

Wed, 09 Sep 2026 07:26:54 -0400

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating and $70.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented: "For aleniglipron, the ACCESS OLE showed 16.2% weight loss at 72 weeks with no plateau in the top dose, achieved on roughly 7.3 weeks of median 180 mg exposure, and AE discontinuations of 2.6% on the 2.5 mg start dose that Phase 3 uses, all supporting our best-in-class, commercially viable thesis, in our opinion. We think step-size design along with the starting dose drove the tolerability improvement, which in our view answers the titration debate. As for the amylin program,

Structure Therapeutics (GPCR) Reiterated at Market Outperform by Citizens

Wed, 09 Sep 2026 04:24:32 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $110.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented, "Structure’s small molecule engine is humming with durable and clean 72-week follow-up for aleniglipron and the first-in-human data for ACCG-2671 confirming its target engagement; we reiterate our Market Outperform rating and maintain our DCF-derived, risk adjusted $110 price target on Structure Therapeutics."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $40.38 yesterday.

Jefferies Reiterates Buy Rating on Structure Therapeutics (GPCR)

Tue, 08 Sep 2026 09:37:43 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $125.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst comments "Bottom line. We see first small molecule amylin ACCG-2671 data hit our bull case (PREVIEW), including PK/ safety/ GI tolerability/ weight loss, and exceeded our (likely investors') expectations on peptide-like weight loss despite in normal BMI + bone benefit signals. Co plans to test both QD and QW dosing in Ph2a 12W study, and we believe data in 1H27 will be highly valuable as could: 1) validate at least competitive profile as a first-in-class SM oral; 2) increase strategic value as

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Tue, 08 Sep 2026 08:00:00 -0400

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Tue, 08 Sep 2026 08:00:00 -0400

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September:

2026 Cantor Global Healthcare Conference
Date: Thursday, September 10
Format: Fireside chat and 1x1 meetings
Time: 3:55 – 4:25 PM EDT
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Date: Wednesday, September 16
Format: Fireside chat and 1x1 meetings
Time: 10:45 – 11:20 AM EDT
Location: New

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September:

2026 Cantor Global Healthcare Conference
Date: Thursday, September 10
Format: Fireside chat and 1x1 meetings
Time: 3:55 – 4:25 PM EDT
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Date: Wednesday, September 16
Format: Fireside chat and 1x1 meetings
Time: 10:45 – 11:20 AM EDT
Location: New

Form 4 Structure Therapeutics For: Aug 18 Filed by: Lin Xichen

Wed, 19 Aug 2026 20:23:00 -0400
si-local-file:///var/storage/secattach/20260819/26951602.html

Form 4 Structure Therapeutics For: Aug 18 Filed by: Lin Xichen

Wed, 19 Aug 2026 20:23:00 -0400
si-local-file:///var/storage/secattach/20260819/26951602.html

Form 4 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260807/26891083.html

Form 4 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260807/26891083.html

Form 3 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260807/26891015.html

Form 3 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260807/26891015.html

Structure Therapeutics (GPCR) PT Lowered to $110 at Citizens

Fri, 07 Aug 2026 07:26:04 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $110.00 (from $113.00) while maintaining a Market Outperform rating.
The analyst commented, "We continue to view aleniglipron as a potential best-in-class, small-molecule GLP agonist and the start of the Phase 3 ACCOMPLISH program marks an important milestone for the company. We are also looking to additional Phase 2 readouts throughout the rest of the year that should further support the improved tolerability profile of starting at a 2.5 mg dose – which is being utilized in Phase 3. We also note GPCR’s oral amylin candidates are progressing

Structure Therapeutics (GPCR) PT Lowered to $110 at Citizens

Fri, 07 Aug 2026 07:26:04 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $110.00 (from $113.00) while maintaining a Market Outperform rating.
The analyst commented, "We continue to view aleniglipron as a potential best-in-class, small-molecule GLP agonist and the start of the Phase 3 ACCOMPLISH program marks an important milestone for the company. We are also looking to additional Phase 2 readouts throughout the rest of the year that should further support the improved tolerability profile of starting at a 2.5 mg dose – which is being utilized in Phase 3. We also note GPCR’s oral amylin candidates are progressing

Form 10-Q Structure Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884663.html

Form 10-Q Structure Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884663.html

Form 8-K Structure Therapeutics For: Aug 06

Thu, 06 Aug 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260806/26884184.html

Form 8-K Structure Therapeutics For: Aug 06

Thu, 06 Aug 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260806/26884184.html

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Thu, 06 Aug 2026 16:05:00 -0400

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)
Phase 3 ACCOMPLISH program for chronic weight management

Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026

Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026;
data from body composition, type 2 diabetes/obesity and SWITCH clinical trials
on track for Q4 2026

Appointed metabolic commercial industry veteran John Berrios as Chief Commercial Officer

Cash, cash

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Thu, 06 Aug 2026 16:05:00 -0400

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)
Phase 3 ACCOMPLISH program for chronic weight management

Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026

Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026;
data from body composition, type 2 diabetes/obesity and SWITCH clinical trials
on track for Q4 2026

Appointed metabolic commercial industry veteran John Berrios as Chief Commercial Officer

Cash, cash

Form SCHEDULE 13G/A Structure Therapeutics Filed by: FMR LLC

Thu, 06 Aug 2026 10:41:00 -0400
si-local-file:///var/storage/secattach/20260806/26881385.html

Form SCHEDULE 13G/A Structure Therapeutics Filed by: FMR LLC

Thu, 06 Aug 2026 10:41:00 -0400
si-local-file:///var/storage/secattach/20260806/26881385.html

Form 4 Structure Therapeutics For: Aug 04 Filed by: Lin Xichen

Wed, 05 Aug 2026 16:50:00 -0400
si-local-file:///var/storage/secattach/20260805/26875444.html

Form 4 Structure Therapeutics For: Aug 04 Filed by: Lin Xichen

Wed, 05 Aug 2026 16:50:00 -0400
si-local-file:///var/storage/secattach/20260805/26875444.html